Discontinued — last reported Q4 '25
Products & Services · Intangible assets
Winrevair — Intangible assets
Merck & Co. Winrevair — Intangible assets decreased by 8.5% to $5.40B in Q4 2025 compared to the prior quarter.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2024
Last reportedQ4 2025
Rolls up toIntangible assets — net
How to read this metric
An increase typically reflects capitalized development costs or acquisitions, while a decrease suggests amortization or potential impairment charges.
Detailed definition
This metric represents the net book value of capitalized intellectual property, patents, and acquired rights associated...
Peer comparison
Comparable to capitalized R&D or acquired intangible assets reported by other biopharmaceutical firms for specific therapeutic assets.
Metric ID:
mrk_segment_winrevair_intangible_assetsHistorical Data
2 periods
| Q4 '24 | Q4 '25 | |
|---|---|---|
| Value | $5.90B | $5.40B |
| QoQ Change | — | -8.5% |
| YoY Change | — | -8.5% |
Range$5.40B – $5.90B
Avg YoY Growth-8.5%
Median YoY Growth-8.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s winrevair — intangible assets?
- Merck & Co. (MRK) reported winrevair — intangible assets of $5.40B in Q4 2025.
- What does winrevair — intangible assets mean?
- The total accounting value of the patents and intellectual property rights for this specific drug.